ITEM 8.01. Other Events
Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the
"Company"), a clinical-stage biotechnology company developing monoclonal
antibodies that target various cancer types, issued a press release on January
25, 2023 announcing the completion of the dosing period of its Phase I Clinical
Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a
treatment for brain cancer.
A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by this reference.
ITEM 9.01. Financial Statements and Exhibits
Exhibit No. Description
99.1* Press Release, dated January 25, 2023
104* Cover Page Interactive Data File (formatted as Inline XBRL and
contained in Exhibit 101)
*Furnished herewith
2
© Edgar Online, source Glimpses